2020
Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers
Kantrowitz JT, Grinband J, Goff DC, Lahti AC, Marder SR, Kegeles LS, Girgis RR, Sobeih T, Wall MM, Choo TH, Green MF, Yang YS, Lee J, Horga G, Krystal JH, Potter WZ, Javitt DC, Lieberman JA. Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers. Neuropsychopharmacology 2020, 45: 1842-1850. PMID: 32403118, PMCID: PMC7608251, DOI: 10.1038/s41386-020-0706-z.Peer-Reviewed Original ResearchConceptsDorsal anterior cingulate cortexBrief Psychiatric Rating ScaleTS-134Target engagementHealthy volunteersMetabotropic glutamate receptor 2/3 agonistKetamine-induced psychotic symptomsBPRS positive symptomsDouble-blind conditionsProof of mechanismKetamine-induced changesAntipsychotic drug developmentTreatment of schizophreniaPsychiatric Rating ScaleAnterior cingulate cortexPrimary outcomeClinical symptomsGlutamatergic drugsGlutamate neurotransmissionTotal symptomsClinical assessmentLow dosePsychotic symptomsHigh dosePlacebo data
1993
Long-Term Outcome of Panic Disorder After Short-Term Imipramine and Behavioral Group Treatment
NAGY L, KRYSTAL J, CHARNEY D, MERIKANGAS K, WOODS S. Long-Term Outcome of Panic Disorder After Short-Term Imipramine and Behavioral Group Treatment. Journal Of Clinical Psychopharmacology 1993, 13: 16-24. PMID: 8098050, DOI: 10.1097/00004714-199302000-00003.Peer-Reviewed Original ResearchConceptsMonths of treatmentLong-term outcomesTime of admissionTime of dischargeEfficacy of treatmentPanic attack frequencyDSM-III diagnosesBehavioral treatment programBehavioral group treatmentNonpharmacological therapiesTerm outcomesMajor depressionAntipanic medicationSame doseLow doseLifetime diagnosisTreatment durationPatientsPanic disorderPanic attacksAttack frequencyImipramineTreatment programBehavioral therapyImpairment ratingsEnhanced suppression of cortisol following dexamethasone administration in posttraumatic stress disorder
Yehuda R, Southwick SM, Krystal JH, Bremner D, Charney DS, Mason JW. Enhanced suppression of cortisol following dexamethasone administration in posttraumatic stress disorder. American Journal Of Psychiatry 1993, 150: 83-86. PMID: 8417586, DOI: 10.1176/ajp.150.1.83.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderDexamethasone administrationDexamethasone levelsLow-dose dexamethasone suppression testEnhanced negative feedback sensitivityStress disorderBaseline blood samplesDexamethasone suppression testNegative feedback sensitivityMale patientsHPA abnormalitiesSuppression testMajor depressionBlood samplesLow doseDiagnostic criteriaNormal subjectsPTSD patientsPatientsDexamethasoneCortisolGreater suppressionFeedback sensitivityEnhanced suppressionAdministration
1989
Clinical and Medication Outcome After Short-term Alprazolam and Behavorial Group Treatment in Panic Disorder: 2.5-Year Naturalistic Follow-up Study
Nagy LM, Krystal JH, Woods SW, Charney DS. Clinical and Medication Outcome After Short-term Alprazolam and Behavorial Group Treatment in Panic Disorder: 2.5-Year Naturalistic Follow-up Study. JAMA Psychiatry 1989, 46: 993-999. PMID: 2818144, DOI: 10.1001/archpsyc.1989.01810110035005.Peer-Reviewed Original ResearchConceptsFU periodAlprazolam treatmentMajor depressionPanic disorderPanic attacksPanic attack frequencyBehavioral group treatment programGreater symptom severityAntipanic effectsNonpharmacologic therapiesMedication outcomesNaturalistic followGroup treatment programAlprazolam dosesSame doseLow doseLifetime diagnosisAttack frequencySymptom severityTreatment programBehavioral therapyPatientsAdmissionAlprazolamTreatment gains